Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
By Angus Liu,
Fierce Pharma
| 02. 21. 2025
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez.
The New York pharma is ending global development and commercialization of Beqvez less than a year after an FDA approval for the gene therapy to treat hemophilia B. The one-time treatment carried a list price of $3.5 million per person.
Several reasons led to the discontinuation, including limited interest from patients and doctors toward hemophilia gene therapies to date, a Pfizer spokesperson told Fierce Pharma in a statement.
No patients seem to have received commercial Beqvez since its FDA nod in April 2024. The Pfizer spokesperson said the company will communicate the news to patients and providers that are in the treatment qualification process, adding that the company remains committed to supporting those who received the med in any clinical trial.
Following Beqvez’s exit from the market, Pfizer has no commercial or clinical-stage gene therapies left in the works, according to its website. The spokesperson confirmed that the company doesn’t have any active gene therapy programs at the moment.
Step by step...
Related Articles
By Jared Whitlock, Endpoints News | 10.09.2025
When Nirnay Murthy learned about a treatment for his toddler son’s rare condition, relief quickly gave way to disappointment.
A one-time gene therapy called Zolgensma from the Swiss drugmaker Novartis can halt spinal muscular atrophy, a deadly condition that causes...
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Daniel Hildebrand, The Humanist | 10.01.2025
When most people hear the word eugenics, they think of dusty history textbooks and black-and-white photographs: forced sterilizations in the early 20th century, pseudoscientific charts measuring skulls, the language of “fitness” used to justify violence and exclusion. It feels like...
